title: Association of genetic polymorphisms with response to bevacizumab for neovascular age-related macular degeneration in the Chinese population.
abstract: OBJECTIVE
  To determine whether there is an association between CFH, ARMS2, HTRA1, VEGF, SERPING1 or C3 genotypes and patient response to treatment with intravitreal bevacizumab for neovascular age-related macular degeneration (AMD).
  
  
  METHODS
  This was a multicenter prospective study. One hundred and forty four patients with neovascular AMD treated with bevacizumab were recruited from 13 centers. Twelve SNPs were genotyped using Sequenom. Visual acuity score (VAS), central retinal thickness and maximum thickness of lesion were measured at each visit.
  
  
  RESULTS
  For the CFH rs800292 polymorphism, mean VAS changes were 4.4, 8.7 and 15.5 letters in the CC, CT and TT genotype carriers (p = 0.009). For ARMS2 rs10490924, mean VAS changes were 3.6, 12.1 and 9.6 letters for the TT, TG and GG genotypes (p = 0.001). For HTRA1 rs11200638, mean VAS changes were 3.6, 12.3 and 9.6 letters for the AA, AG and GG genotypes (p < 0.001).
  
  
  CONCLUSIONS
  CFH, ARMS2 and HTRA1 genotypes may influence patient response to treatment with intravitreal bevacizumab for neovascular AMD.
authors.affiliation: Department of Epidemiology & Biostatistics, School of Public Health, Peking University Health Science Center, Beijing, Peoples Republic of China.
authors.forename: Jun
authors.initials: J
authors.lastname: Tian
authors.forename: Xueying
authors.initials: X
authors.lastname: Qin
authors.forename: Kai
authors.initials: K
authors.lastname: Fang
authors.forename: Qing
authors.initials: Q
authors.lastname: Chen
authors.forename: Jing
authors.initials: J
authors.lastname: Hou
authors.forename: Juan
authors.initials: J
authors.lastname: Li
authors.forename: Wenzhen
authors.initials: W
authors.lastname: Yu
authors.forename: Dafang
authors.initials: D
authors.lastname: Chen
authors.forename: Yonghua
authors.initials: Y
authors.lastname: Hu
authors.forename: Xiaoxin
authors.initials: X
authors.lastname: Li
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D000068258:Bevacizumab; D054316:Biomarkers, Pharmacological / Q000097:blood*; D002681:China; D003174:Complement C1 Inactivator Proteins / Q000235:genetics; D050718:Complement C1 Inhibitor Protein; D017242:Complement Factor H / Q000235:genetics; D056726:Genetic Association Studies; D000074289:High-Temperature Requirement A Serine Peptidase 1; D006801:Humans; D008268:Macular Degeneration / Q000188:drug therapy* / Q000235:genetics*; D020641:Polymorphism, Single Nucleotide; D011506:Proteins / Q000235:genetics; D012697:Serine Endopeptidases / Q000235:genetics; D042461:Vascular Endothelial Growth Factor A / Q000235:genetics; D014792:Visual Acuity / Q000187:drug effects / Q000235:genetics
chemical_list: C514392:ARMS2 protein, human; D061067:Antibodies, Monoclonal, Humanized; D054316:Biomarkers, Pharmacological; D003174:Complement C1 Inactivator Proteins; D050718:Complement C1 Inhibitor Protein; D011506:Proteins; C469952:SERPING1 protein, human; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab; D017242:Complement Factor H; D000074289:High-Temperature Requirement A Serine Peptidase 1; C474012:HTRA1 protein, human; D012697:Serine Endopeptidases